- Foundayo (orforglipron) is the first oral small-molecule GLP-1 receptor agonist FDA-approved for chronic weight management
- It is a once-daily tablet with no food or water restrictions — take it any time of day
- The ATTAIN-1 trial showed approximately 11% body weight loss (~25 lbs) at the approved 17.2 mg dose over 72 weeks
- Side effects are primarily GI-related (nausea, diarrhea, constipation) and generally improve with gradual titration
- Available through LillyDirect at $149–$299/month, with a savings card bringing costs as low as $25/month for eligible commercial insurance patients
For many patients considering GLP-1 medications for weight loss, the idea of a weekly injection has been a real barrier. Foundayo changes that equation. Approved by the FDA in April 2026, it is the first small-molecule GLP-1 receptor agonist available as a once-daily pill — and unlike other oral options, it comes with no food or water restrictions.
This guide covers everything you need to know about Foundayo (orforglipron): what it is, how it works, clinical trial data, the dosing schedule, side effects, cost, and how it fits alongside other FDA-approved weight loss medications like Wegovy and Zepbound.
What is Foundayo?
Foundayo is the brand name for orforglipron, manufactured by Eli Lilly. It received FDA approval in April 2026 for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related condition.
What makes Foundayo genuinely different from every other GLP-1 weight loss medication on the market is its chemistry. Existing GLP-1 medications — whether injectable like Wegovy and Zepbound, or the oral Wegovy Pill — are peptide-based drugs. Peptides are large molecules that are fragile in the digestive system, which is why most GLP-1 medications require injection, and why the Wegovy Pill requires strict dosing conditions (empty stomach, limited water, 30-minute wait before eating).
Foundayo is a small-molecule drug, not a peptide. This is the key innovation. Small molecules are more stable in the GI tract, which means Foundayo can be taken as a simple daily pill with no food or water restrictions. You can take it in the morning, at lunch, or before bed — whenever works best for your routine.
Generic name: orforglipron
Manufacturer: Eli Lilly
FDA approval: April 2026 for chronic weight management
Form: Once-daily oral tablet
Key advantage: No food or water restrictions — take any time of day
How Foundayo works
Foundayo is a GLP-1 receptor agonist. Like other medications in this class, it works by activating the same receptors that your body’s natural GLP-1 hormone targets. The result is a set of well-established effects that contribute to weight loss.
Appetite reduction
Foundayo acts on GLP-1 receptors in the brain, particularly in the hypothalamus, to reduce appetite and decrease food intake. Patients consistently describe this as a quieting of food noise — the constant background thinking about food and cravings that makes it difficult to sustain a reduced-calorie diet on willpower alone.
Delayed gastric emptying
Like other GLP-1 medications, Foundayo slows the rate at which food leaves the stomach and enters the small intestine. This means you feel full longer after eating, which naturally reduces portion sizes and between-meal snacking. This mechanism is also why GI side effects (particularly nausea) are common during the early titration phase — your stomach is adjusting to a new pace of digestion.
Small molecule vs. peptide
The critical difference between Foundayo and every other approved GLP-1 medication is molecular structure. Peptide-based GLP-1s (semaglutide, tirzepatide, liraglutide) are large, fragile molecules that break down in the digestive system. That is why most are injected, and why the one oral peptide option (Wegovy Pill) requires specific dosing conditions to protect the drug from degradation.
Foundayo’s small-molecule structure survives the GI tract without special protection, which eliminates the need for injections and removes the dosing restrictions that apply to oral semaglutide. This is not just a convenience improvement — for patients who struggle with injection anxiety or cannot reliably follow the Wegovy Pill’s morning-fasting protocol, it removes a genuine barrier to treatment.
Clinical trial results
The FDA approval of Foundayo for weight management was supported by the ATTAIN-1 clinical trial, a large, randomized, placebo-controlled study that evaluated the drug’s efficacy and safety over 72 weeks.
ATTAIN-1 trial overview
ATTAIN-1 enrolled 3,127 adults with obesity or overweight with at least one weight-related condition. Participants were randomized to receive Foundayo at various doses or placebo, all as an adjunct to a reduced-calorie diet and increased physical activity.
At the approved maintenance dose of 17.2 mg, participants lost approximately 11% of their body weight — roughly 25 pounds — over 72 weeks. Approximately 55% of participants achieved 10% or greater weight loss, a threshold that is clinically meaningful and associated with improvements in blood pressure, blood sugar, and other weight-related health markers.
An 11% average weight loss is clinically significant and represents a meaningful improvement over diet and exercise alone. For a 230-pound patient, that is roughly 25 pounds. While this is less than the averages reported for injectable semaglutide (~15%) or tirzepatide (~20–22.5%), Foundayo offers the trade-off of a simple daily pill with no injection and no dosing restrictions. The right medication depends on your goals, preferences, and clinical profile — not just the highest number on a chart.
The ATTAIN-1 trial also evaluated higher investigational doses of orforglipron that are not included in the current approved labeling. The FDA approval is based on the 17.2 mg dose.
Dosing and titration schedule
Like all GLP-1 medications, Foundayo uses a gradual dose titration schedule. You start at a low dose and increase over time, which allows your body to adjust and minimizes side effects. The titration for Foundayo involves six dose levels:
- 0.8 mg — starting dose (at least 30 days)
- 2.5 mg — second step (at least 30 days)
- 5.5 mg — third step (at least 30 days)
- 9 mg — fourth step (at least 30 days)
- 14.5 mg — fifth step (at least 30 days)
- 17.2 mg — maintenance dose
Each dose level requires at least 30 days before advancing to the next. This means the full titration from starting dose to maintenance takes approximately five to six months. Your clinician may extend time at any dose level if side effects need more time to resolve.
If you miss seven or more consecutive doses of Foundayo, you may need to restart at a lower dose rather than resuming your current level. This is to avoid the GI side effects that can occur when restarting at a higher dose without gradual titration. If you miss doses, contact your care team before resuming.
One practical advantage of Foundayo’s dosing: because there are no food or water restrictions, adherence is straightforward. Take one tablet daily at whatever time works for you. There is no need to set an alarm for an empty-stomach window or plan your morning around a 30-minute wait.
Side effects
Foundayo’s side effect profile is consistent with the GLP-1 medication class. The most common side effects are gastrointestinal and tend to be most pronounced during the dose titration phase.
Common side effects
- Nausea — the most frequently reported side effect, affecting approximately 35% of patients in clinical trials. Typically mild to moderate and improves as your body adjusts to each new dose level.
- Diarrhea — reported in some patients, usually temporary. Staying hydrated is important.
- Constipation — can occur as digestion slows. Adequate fiber, hydration, and physical activity help manage this.
- Indigestion (dyspepsia) — stomach discomfort or heartburn, typically mild and transient.
For most patients, these side effects are manageable and tend to improve with gradual titration. The six-step dose escalation schedule is specifically designed to minimize GI discomfort by giving your body time to adjust at each level.
Serious warnings
Foundayo carries additional warnings that apply to the GLP-1 medication class:
- Pancreatitis: Inflammation of the pancreas has been reported with GLP-1 medications. Seek medical attention for severe, persistent abdominal pain.
- Gallbladder disease: GLP-1 medications may increase the risk of gallstones and gallbladder inflammation.
- Gastroparesis: Patients with pre-existing severe gastroparesis should discuss risks with their provider.
- Acute kidney injury: Can occur secondary to dehydration from GI side effects. Maintaining adequate hydration is important.
- Pulmonary aspiration: Due to delayed gastric emptying, patients should inform their anesthesiologist before any procedures requiring sedation.
- Pregnancy: Foundayo may cause fetal harm. It should be discontinued at least two months before a planned pregnancy.
Oral contraceptive interaction
Foundayo may affect the absorption of oral contraceptives, though this interaction has not been fully evaluated in clinical trials. If you take oral birth control, the labeling recommends using a non-oral contraceptive method or adding a barrier method as backup for 30 days after starting Foundayo and after each dose increase.
How Foundayo compares to other GLP-1 medications
Foundayo enters a market with several established GLP-1 weight loss medications. Here is a brief comparison of the key differences that matter for patients.
Foundayo vs. Wegovy
Wegovy (semaglutide) is a once-weekly injection that has been the most widely prescribed GLP-1 for weight loss since 2021. Clinical trials showed approximately 15% body weight loss. Wegovy also has cardiovascular outcome data from the SELECT trial and is approved for adolescents. If you prioritize maximum weight loss and are comfortable with injections, Wegovy remains an excellent option.
Foundayo vs. Zepbound
Zepbound (tirzepatide) is a once-weekly injection and a dual GLP-1/GIP receptor agonist. It showed approximately 20–22.5% body weight loss in clinical trials — the highest of any approved weight loss medication. Zepbound is also approved for obstructive sleep apnea. For patients seeking the greatest possible weight loss and who are comfortable with injections, Zepbound typically produces the strongest results.
Foundayo vs. Wegovy Pill
The Wegovy Pill (oral semaglutide) is the other oral GLP-1 option, showing approximately 15% weight loss in clinical trials. However, the Wegovy Pill is a peptide that requires strict dosing conditions: it must be taken on an empty stomach in the morning with no more than 4 ounces of water, and you must wait at least 30 minutes before eating, drinking, or taking other medications. Foundayo has none of these restrictions, which makes daily adherence significantly simpler.
The best weight loss medication is the one you can take consistently. For patients who want an oral option without the dosing restrictions of the Wegovy Pill and without the injections of Wegovy or Zepbound, Foundayo fills a gap that did not exist before.
Cost and insurance coverage
As a newly approved medication, Foundayo’s insurance coverage landscape is still developing. Here is what we know about pricing and coverage as of April 2026.
Cash pricing
Through LillyDirect (Eli Lilly’s direct-to-patient platform), Foundayo is priced at $149 to $299 per month, depending on the dose. This is notably lower than the list prices of injectable GLP-1 medications, which has been one of the most anticipated aspects of an oral small-molecule option.
Savings card
Eli Lilly offers a Foundayo savings card for patients with eligible commercial insurance, which can bring out-of-pocket costs as low as $25 per month. This savings card is subject to annual caps and is not valid for patients with government insurance (Medicare, Medicaid, TRICARE).
Medicare Part D
Medicare Part D coverage for Foundayo at $50 per month is expected to begin in July 2026. PEAK does not accept Medicare, but this information may be relevant for patients exploring all their options.
Commercial insurance
Coverage through commercial insurance plans is being established as carriers add Foundayo to their formularies. Prior authorization will likely be required by most plans. At PEAK, we accept Anthem, Cigna, Aetna, UHC, Sentara, and TRICARE (commercial plans) and our insurance team handles the prior authorization process and savings card enrollment for every patient.
Beyond the medication itself, PEAK’s clinical program includes an initial provider visit ($199 self-pay), follow-up visits ($135), and dietitian visits ($75/visit). These office visits are billed separately from the medication and may be covered by your insurance. Our team helps you understand the full cost picture before treatment begins.
Who is a good candidate for Foundayo?
Foundayo shares the same general eligibility criteria as other FDA-approved weight loss medications: adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Beyond the clinical criteria, Foundayo may be a particularly good fit if you:
- Prefer a pill over injections. If needle anxiety or injection fatigue is a barrier, Foundayo removes it entirely.
- Want a simple dosing routine. No empty stomach requirements, no water restrictions, no 30-minute wait. Take it whenever works for your schedule.
- Have tried the Wegovy Pill but struggled with the morning fasting protocol. Foundayo offers the convenience of a pill without the strict dosing conditions.
- Are looking for a lower-cost oral option. At $149–$299/month through LillyDirect (or as low as $25/month with the savings card), Foundayo may be more accessible than some alternatives.
Foundayo is not appropriate for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or patients with a known serious hypersensitivity to orforglipron.
Your provider will evaluate your full medical history, current medications, and health goals to determine whether Foundayo is the right choice for you. At PEAK, that evaluation happens during your initial consultation, and we will also factor in your insurance coverage to help you make the most practical decision.
Frequently asked questions
Foundayo is a once-daily oral tablet. It is the first small-molecule GLP-1 receptor agonist, which means it does not require injection. Unlike the Wegovy Pill, Foundayo has no food or water restrictions — you can take it any time of day, with or without food.
Foundayo uses a six-step titration schedule, starting at 0.8 mg and increasing through 2.5, 5.5, 9, and 14.5 mg before reaching the maintenance dose of 17.2 mg. Each step requires at least 30 days, so the full titration takes approximately five to six months. Your clinician may extend time at any dose level if needed to manage side effects.
In clinical trials, Foundayo (17.2 mg) produced approximately 11% body weight loss over 72 weeks. Wegovy (injectable semaglutide) showed approximately 15%, and Zepbound (injectable tirzepatide) showed approximately 20–22.5%. While Foundayo produces less weight loss on average, it offers the convenience of a daily pill with no injection and no food or water restrictions. The best medication depends on your individual goals, preferences, and clinical profile. See our detailed comparisons: Foundayo vs. Wegovy, Foundayo vs. Zepbound, and Foundayo vs. Wegovy Pill.
Foundayo may affect the absorption of oral contraceptives, though this interaction has not been fully evaluated in clinical trials. The labeling recommends using a non-oral contraceptive method or adding a barrier method (such as condoms) as backup for 30 days after starting Foundayo and after each dose increase. Discuss your contraceptive plan with your provider before starting treatment.
Through LillyDirect, Foundayo is priced at $149 to $299 per month. Eli Lilly’s savings card can bring the cost as low as $25 per month for patients with eligible commercial insurance (subject to annual caps; not valid for government insurance). Insurance coverage is still being established as carriers add Foundayo to their formularies. At PEAK, our insurance team verifies your coverage and helps with prior authorization and savings card enrollment before treatment begins.
Clinical references
- Foundayo (orforglipron) prescribing information. Eli Lilly and Company. April 2026.
- ATTAIN-1: A randomized, double-blind, placebo-controlled, phase 3 trial of orforglipron for chronic weight management. ClinicalTrials.gov.
- U.S. Food and Drug Administration. FDA approves Foundayo (orforglipron) for chronic weight management. April 2026.
- Wegovy (semaglutide) prescribing information. Novo Nordisk. 2021 (updated 2025).
- Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. 2023 (updated 2025).
Boxed warning — thyroid C-cell tumors: Foundayo (orforglipron) carries an FDA boxed warning about thyroid C-cell tumors based on findings with other GLP-1 receptor agonists in rodents. Orforglipron itself was not active in rodent thyroid C-cells and did not produce thyroid C-cell tumors in animal studies. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
Indication: Foundayo is FDA-approved for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
